Ascendiant Capital Markets Cuts Alzamend Neuro (NASDAQ:ALZN) Price Target to $45.00

Alzamend Neuro (NASDAQ:ALZN) had its price target lowered by Ascendiant Capital Markets from $180.00 to $45.00 in a report issued on Thursday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Separately, Wall Street Zen downgraded Alzamend Neuro from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $45.00.

Alzamend Neuro Stock Up 6.0%

Shares of ALZN opened at $2.49 on Thursday. The stock has a 50 day moving average of $2.79 and a 200 day moving average of $5.27. Alzamend Neuro has a 12 month low of $2.06 and a 12 month high of $31.40.

Insiders Place Their Bets

In other Alzamend Neuro news, Director Milton C. Ault III sold 100,000 shares of the stock in a transaction on Thursday, July 31st. The stock was sold at an average price of $2.22, for a total transaction of $222,000.00. Following the completion of the transaction, the director directly owned 8,260 shares of the company’s stock, valued at approximately $18,337.20. This represents a 92.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 243,429 shares of company stock worth $627,895 over the last three months. 30.21% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Geode Capital Management LLC purchased a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned 0.62% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is currently owned by institutional investors and hedge funds.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.